Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Suven Life Sciences rises on securing product patents in Mexico, New Zealand

07-Aug2018

Suven Life Sciences rises on securing product patents in Mexico, New Zealand

Suven Life Sciences is currently trading at Rs. 226.40, up by 1.30 points or 0.58% from its previous closing of Rs. 225.10 on the BSE.

The scrip opened at Rs. 225.00 and has touched a high and low of Rs. 228.85 and Rs. 224.40 respectively. So far 26023 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 250.80 on 29-Jan-2018 and a 52 week low of Rs. 155.00 on 11-Aug-2017.

Last one week high and low of the scrip stood at Rs. 234.00 and Rs. 220.00 respectively. The current market cap of the company is Rs. 2881.68 crore.

The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 6.69% and 33.31% respectively.

Suven Life Sciences has secured one product patent from Mexico and one product patent from New Zealand corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2030 and 2036 respectively.

The granted claims of the patents include the class of selective H3 and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.


Related News

View all news

Reliance Infrastructure trades in green on the bourses

Reliance Infrastructure is currently trading at Rs. 356.00, up by 3.15 points or 0.89% from its previous closing of Rs. 352.85 on the BSE.The scrip opened at Rs. 351.90 and has touched a high and low of......

M&M gains on the BSE

Mahindra & Mahindra is currently trading at Rs. 787.10, up by 6.75 points or 0.86% from its previous closing of Rs. 780.35 on the BSE.The scrip opened at Rs. 782.00 and has touched a high and low......

Alembic Pharma advances on the bourses

Alembic Pharmaceuticals is currently trading at Rs. 571.50, up by 8.90 points or 1.58% from its previous closing of Rs. 562.60 on the BSE.The scrip opened at Rs. 572.95 and has touched a high and low of......

Top News

View all news

Jumbo Finance gets shareholders' nod to increase borrowing limits up to Rs 30 crore

Jumbo Finance has received an approval to increase Borrowing Limits of the company up-to Rs 30 crore. The shareholders of the company at their meeting held on November 19, 2018, approved the same.Jumbo......

Alembic Pharma gets USFDA's nod for Vardenafil Hydrochloride Orally Disintegrating Tablets

Alembic Pharmaceuticals has received an approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Vardenafil Hydrochloride Orally Disintegrating Tablets,......

SRF expects total Rs 28 crore quantum of damage due to Cyclone GAJA

SRF is expecting a total Rs 28 crore quantum of damage caused, based on the initial assessment. The disruption of operations was due to Cyclone GAJA at the plant of Technical Textiles Business (Viralimalai)......